Deprecated: The each() function is deprecated. This message will be suppressed on further calls in /home/zhenxiangba/zhenxiangba.com/public_html/phproxy-improved-master/index.php on line 456
JPH0255410B2 - - Google Patents
[go: Go Back, main page]

JPH0255410B2 - - Google Patents

Info

Publication number
JPH0255410B2
JPH0255410B2 JP56012579A JP1257981A JPH0255410B2 JP H0255410 B2 JPH0255410 B2 JP H0255410B2 JP 56012579 A JP56012579 A JP 56012579A JP 1257981 A JP1257981 A JP 1257981A JP H0255410 B2 JPH0255410 B2 JP H0255410B2
Authority
JP
Japan
Prior art keywords
mannitol
freeze
aqueous solution
water
drying
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP56012579A
Other languages
Japanese (ja)
Other versions
JPS57128643A (en
Inventor
Shinya Nagashima
Eiichiro Suzuki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ajinomoto Co Inc
Original Assignee
Ajinomoto Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ajinomoto Co Inc filed Critical Ajinomoto Co Inc
Priority to JP1257981A priority Critical patent/JPS57128643A/en
Publication of JPS57128643A publication Critical patent/JPS57128643A/en
Publication of JPH0255410B2 publication Critical patent/JPH0255410B2/ja
Granted legal-status Critical Current

Links

Landscapes

  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Description

【発明の詳細な説明】 本発明は、新規凍結乾燥方法に関し、その目的
とするところは、微細で溶解性に優れたマンニト
ール含有凍結乾燥品の提供にある。
DETAILED DESCRIPTION OF THE INVENTION The present invention relates to a novel freeze-drying method, and its purpose is to provide a freeze-dried product containing fine mannitol with excellent solubility.

マンニトール含有凍結乾燥品、特に注射剤のた
めに有用なマンニトール賦形剤とする凍結乾燥製
剤として従来品に比較し、微細で溶解性に優れた
ものが要望されている。
There is a demand for a lyophilized mannitol-containing product, particularly a lyophilized preparation that is a useful mannitol excipient for injections, and is finer and more soluble than conventional products.

本発明者は、マンニトール含有水性溶液の凍結
乾燥方法において、凍結工程における品温の冷却
速度を少なくとも1度/分、好ましくは1〜10
度/分、さらに好ましくは冷却のためのエネルギ
ーコストの点で2〜4度/分にすることにより、
上記の如く優れた諸性質を有する製品を取得でき
ることを見出し、この発見に基づいて本発明を完
成するに至つた。
In the freeze-drying method of an aqueous solution containing mannitol, the present inventor has determined that the cooling rate of the product temperature in the freezing step is at least 1 degree/minute, preferably 1 to 10 degrees/min.
degrees/min, more preferably 2 to 4 degrees/min in terms of energy costs for cooling.
The inventors have discovered that it is possible to obtain a product having excellent properties as described above, and have completed the present invention based on this discovery.

凍結乾燥は凍結工程とそれに次ぐ乾燥工程によ
り成り立つているが、凍結工程において従来実施
されていたような毎分1度以下の遅い冷却速度で
は、冷却工程の途中で析出物が生成し、例えば直
径1mm以上の球状晶が含まれ、外観および溶解性
の点で必ずしも満足すべき粉末を与えない。これ
に対し、本発明によれば、冷却工程の途中で析出
物が生成することはなく、前記球状晶も見出され
ず。外観の点でも溶解性の点でもより満足のゆく
粉末を得ることができ、特に医薬品分野において
本発明は極めて意義がある。
Freeze-drying consists of a freezing step and a subsequent drying step. However, if the cooling rate is slow, less than 1 degree per minute, which is conventionally used in the freezing process, precipitates are formed during the cooling process, and for example, It contains spherical crystals of 1 mm or more, and does not give a powder that is necessarily satisfactory in terms of appearance and solubility. On the other hand, according to the present invention, no precipitates are generated during the cooling process, and no spheroidal crystals are found. It is possible to obtain a powder that is more satisfactory in both appearance and solubility, and the present invention is extremely significant, particularly in the pharmaceutical field.

本発明において使用するマンニトール含有水性
溶液は、少なくともマンニトールを含有した水を
主体とする均一溶液である。マンニトールの濃度
は例えば全水分に対し1〜10%程度である。もち
ろん、その他の成分、例えば医薬活性成分を含有
せしめることができる。その場合、その他の成分
の濃度は全水分に対し0.01〜1%程度である。
The mannitol-containing aqueous solution used in the present invention is a homogeneous solution mainly composed of water containing at least mannitol. The concentration of mannitol is, for example, about 1 to 10% of the total water. Of course, other ingredients can be included, such as pharmaceutically active ingredients. In that case, the concentration of other components is about 0.01 to 1% based on the total water content.

本発明における凍結乾燥の操作は、それ自体公
知方法を利用して実施すればよい。
The freeze-drying operation in the present invention may be carried out using a method known per se.

なお、試料のマンニトール含有水性溶液をビー
カー、広口びん等弱い容器中に入れ、これを真空
系内で凍結乾燥するとき、特にマンニトール濃度
が全水分に対し3%以上であるとき、マンニトー
ルの結晶化に伴い、放出された水和水の再結晶の
ためか、内容物の体積膨脹による衝撃により容器
が破壊してしまう。これを避けるためには、−22
℃を越えない温度で乾燥工程の初期に全水分の少
なくとも1%の水分が気化する条件を選択し、乾
燥工程を実施すればよい。
In addition, when a sample mannitol-containing aqueous solution is placed in a weak container such as a beaker or a wide-mouth bottle and freeze-dried in a vacuum system, crystallization of mannitol may occur, especially when the mannitol concentration is 3% or more based on the total water content. Due to the recrystallization of the released hydration water, the container breaks due to the impact caused by the volumetric expansion of the contents. To avoid this, −22
The drying process may be carried out by selecting conditions under which at least 1% of the total moisture vaporizes at a temperature not exceeding .degree. C. at the beginning of the drying process.

この点について詳述すると、凍結乾燥の工程は
凍結工程とそれに次ぐ乾燥工程により成り立つて
いるが、マンニトール含有水性溶液を例えばビー
カー等のガラス容器に入れて、これを凍結乾燥の
工程に付すとき、乾燥工程で容器が内容物の体積
膨張による衝撃により割れてしまうことがしばし
ばあつた。このため材質、肉厚、形状等の点で特
殊な容器を採用する必要があつた。
To elaborate on this point, the freeze-drying process consists of a freezing process and a subsequent drying process, but when a mannitol-containing aqueous solution is placed in a glass container such as a beaker and subjected to the freeze-drying process, During the drying process, the containers often broke due to the impact caused by the volumetric expansion of the contents. For this reason, it was necessary to use a special container in terms of material, wall thickness, shape, etc.

本発明者は、上記問題点をも解決し、弱い容器
を採用しても実施できる方法を開発すべく鋭意研
究を行つた結果、乾燥工程における水分気化条件
を−22度を越えない温度で該工程の初期の全水分
の少なくとも1%、好ましくは少なくとも5%の
水分が気化するような条件を採用すれば解決でき
ることを見出し、この発見に基づいて本発明を完
成するに至つた。
As a result of intensive research to solve the above problems and develop a method that can be carried out even if a weak container is used, the inventor has determined that the moisture evaporation conditions in the drying process are set at a temperature not exceeding -22 degrees Celsius. The inventors have discovered that the problem can be solved by adopting conditions such that at least 1%, preferably at least 5%, of the total moisture at the initial stage of the process is vaporized, and based on this discovery, the present invention has been completed.

すなわち、実施例1に示すように、マンニトー
ル水について凍結−解凍曲線を求めたところ、特
異的な曲線が得られ、特に−22度付近で、溶質の
析出によるとみられる再凍結に由来するピークが
存在することが見出され、これを考慮してさらに
検討を重ねた結果、本発明を完成したものであ
る。
That is, as shown in Example 1, when a freeze-thaw curve was obtained for mannitol water, a specific curve was obtained, and in particular, around -22 degrees, there was a peak derived from refreezing that appeared to be due to precipitation of solutes. It was discovered that there is such a thing, and as a result of further studies taking this into consideration, the present invention was completed.

本発明において使用するマンニトール含有水性
溶液は、少なくともマンニトールを含有し、水を
主体とする均一溶液である。マンニトールの濃度
は、例えば全水分に対し1%以上であればよく濃
度が高いほど乾燥工程時の衝撃は大きいので、本
発明の効果が発揮される。実用上は1〜10%程度
である。もちろん、その他の成分、例えば医薬活
性成分を含有せしめることができる。この場合、
その他の成分の濃度は全水分に対し0.1〜1%程
度であることは前記の通りである。
The mannitol-containing aqueous solution used in the present invention is a homogeneous solution containing at least mannitol and mainly consisting of water. The concentration of mannitol may be, for example, 1% or more based on the total water content, and the higher the concentration, the greater the impact during the drying process, so that the effects of the present invention are exhibited. In practical terms, it is about 1 to 10%. Of course, other ingredients can be included, such as pharmaceutically active ingredients. in this case,
As mentioned above, the concentration of other components is about 0.1 to 1% based on the total water content.

以下、実施例により本発明を詳細に説明する。 Hereinafter, the present invention will be explained in detail with reference to Examples.

実施例 1 次に示す方法により凍結−解凍過程での不凍水
量の変化(凍結−解凍曲線)を求めた。
Example 1 Changes in the amount of antifreeze water (freeze-thaw curve) during the freeze-thaw process were determined by the method shown below.

日本ブルツカー社の「minispec P20」NMR装
置にYHPのHP1000ミニコンシステムを装備した
システムを使用し、外径7mmの試料管を使用し凍
結、解凍の実験に供した。
A system equipped with Nippon Bruzker's "minispec P20" NMR apparatus equipped with YHP's HP1000 minicon system was used for freezing and thawing experiments using sample tubes with an outer diameter of 7 mm.

9.1%マンニトール水溶液250mgを試料とし、冷
却降温および加熱昇温速度を6度/分としたとき
の結果を図1に、また0.5度/分としたときの結
果を図2に示した。縦軸は不凍水量(g水/g乾
燥容質)、横軸は温度(℃)である。実線は凍結
曲線であり、破線は解凍曲線である。
Using 250 mg of a 9.1% mannitol aqueous solution as a sample, the results are shown in FIG. 1 when the cooling and heating rates were 6 degrees/min, and FIG. 2 shows the results when the heating rate was 0.5 degrees/min. The vertical axis is the amount of unfrozen water (g water/g dry volume), and the horizontal axis is the temperature (° C.). The solid line is the freezing curve, and the dashed line is the thawing curve.

他の糖アルコール類および糖類、例えばソルビ
トール、キシリトール、ブドウ糖、果糖、乳糖、
およびシヨ糖についても上記同様の実験を繰り返
した。
Other sugar alcohols and sugars such as sorbitol, xylitol, glucose, fructose, lactose,
The same experiment as above was repeated for sucrose and sucrose.

以上の結果、他の糖アルコール類および糖類と
比較し、マンニトールの凍結−解凍曲線は特異的
であることがわかつた。
As a result, it was found that the freeze-thaw curve of mannitol is specific compared to other sugar alcohols and saccharides.

図1から理解される如く、6度/分の速度で冷
却凍結後、加熱解凍すると、途中、−22℃付近で、
溶質の析出によると考えられる再凍結に由来する
ピークが、曲線上に認められる。図1において、
6度/分の冷却速度を変化せしめて1度/分まで
遅めても、ほぼ同じピークを有する図1とほぼ同
様の曲線が得られることを確かめた。
As can be understood from Figure 1, when heated and thawed after being cooled and frozen at a rate of 6 degrees/minute, the temperature at around -22 degrees Celsius,
A peak derived from refreezing, which is thought to be due to solute precipitation, is observed on the curve. In Figure 1,
It was confirmed that even if the cooling rate was changed from 6 degrees/minute to 1 degree/minute, a curve similar to that shown in FIG. 1 with almost the same peaks could be obtained.

通常ゲル以外の糖類、糖アルコール類には顕著
な履歴が認められないのに対し、マンニトール水
溶液では、大きな凍結−解凍履歴ループが観測さ
れた、解凍中の再凍結ピークの高さは、冷媒とし
て液体窒素を使用した場合におけるような超急速
凍結と、1度/分以下の緩慢凍結(図2参照。)
のいずれによつてても、小さくなつたり、消失し
たりする。前者は、マトリツクス分離に近い、ク
ラスター径の小さい、凍結濃縮体が生成するた
め、解凍中に水和水を放出して結晶化する際に単
位重量当たりの放出量が少ないため、後者は、冷
却過程ですでに結晶となつて析出し終つているた
めと考えられる。
Normally, no remarkable history is observed for sugars and sugar alcohols other than gels, whereas a large freeze-thaw history loop was observed for mannitol aqueous solution.The height of the refreeze peak during thawing is Ultra-rapid freezing, such as when using liquid nitrogen, and slow freezing, less than 1 degree/min (see Figure 2).
In either case, it becomes smaller or disappears. The former produces a frozen condensate with a small cluster diameter, which is similar to matrix separation, and the amount released per unit weight is small when hydration water is released during thawing and crystallized. This is thought to be because the crystals have already formed and precipitated during the process.

以上の実験結果を考慮し、マンニトール水溶液
の凍結乾燥を行つた。
Considering the above experimental results, we performed freeze-drying of the mannitol aqueous solution.

マンニトールの9.1%水溶液20mlを採取し、100
mlビーカーに入れ、自然昇温型の凍結乾燥器
(Refrigeration for Science,INC.,
model2281)と、ロータリーポンプ(日立、
160VP)を用いて凍結乾燥を行つた。
Take 20 ml of 9.1% aqueous solution of mannitol and add 100
ml beaker and dry in a natural temperature rise type freeze dryer (Refrigeration for Science, INC.,
model2281) and rotary pump (Hitachi,
Freeze-drying was performed using 160VP).

得られた乾燥品についてオリンパス光学の実体
顕微鏡で倍率16で写真撮影した。
The obtained dried product was photographed using an Olympus optical stereomicroscope at a magnification of 16.

1度/分未満の冷却速度による緩慢凍結では、
針状晶からなる薄片状の大きな球晶(直径1mm以
上)を生成し、外観上および溶解性の好ましくな
いものが得られた。
In slow freezing with a cooling rate of less than 1 degree/minute,
Large, flaky spherulites (diameter 1 mm or more) consisting of needle-like crystals were produced, which had unfavorable appearance and solubility.

一方、1度/分以上の冷却速度による急速凍結
では上記の大きな球晶は生成せず、外観上からも
溶解性からもより好ましいものが得られた。
On the other hand, rapid freezing at a cooling rate of 1 degree/min or more did not produce the above-mentioned large spherulites, and a more preferable product was obtained from both the appearance and solubility standpoints.

さらに、再凍結が起こる、−22℃以下で多くの
氷を昇華させ、間隙をつくらないと、凍結乾燥
中、容器(ビーカー、広口びん等)が割れること
がわかつた。これはマンニトールが、凍結下では
極めて容易に水を離し、これが氷となり体積が膨
張するためである。因みに、溶解性がより好まし
いものとなるのは、この氷が0℃まで融解しない
ので溶質の移動は無く、昇華面後退で凍結乾燥が
進むこととも密接な関連があるものと考えられ、
その結果、他の糖類、糖アルコール類に比べて賦
形剤としてのマンニトールの凍結乾燥効果が優れ
ていることも理解できる。
Furthermore, it was found that containers (beakers, wide-mouthed bottles, etc.) would crack during freeze-drying unless a large amount of ice was sublimated and created a gap at temperatures below -22°C, where refreezing occurs. This is because mannitol very easily releases water under freezing conditions, which turns into ice and expands in volume. Incidentally, the reason why the solubility is more favorable is thought to be closely related to the fact that this ice does not melt down to 0°C, so there is no movement of solutes, and that freeze-drying progresses as the sublimation surface recedes.
As a result, it can be understood that the freeze-drying effect of mannitol as an excipient is superior to that of other sugars and sugar alcohols.

上記の容器の割れを防止するには、乾燥工程に
おいて水分気化条件を−22℃を越えない温度で全
水分の少なくとも1%の水分をまず気化するよう
な条件を選択すればよい。
In order to prevent the above-mentioned container from cracking, moisture vaporization conditions may be selected in the drying process such that at least 1% of the total moisture is vaporized at a temperature not exceeding -22°C.

これは、溶質の重量と同程度の、すなわち図1
に見られる如く、約1g水/g乾燥溶質の水和水
が、解凍過程で再凍結を起こすと考えられるた
め、すなわち再凍結を起こす水の量は、溶質の重
量と同程度であるため、溶質が全水分の3%のと
きは、再凍結する水和水量はやはり全水分の3%
であると考えられ、その場合の衝撃は、少なくと
も全水分の3%の氷が昇華していれば防止できる
と考えられ、凍結乾燥に供せられるマンニトール
の量は一般には全水分の1〜10%であるので、最
少量として1%の水分を該工程の初期に昇華させ
ることによれば十分である。
This is comparable to the weight of the solute, i.e., Figure 1
As seen in Figure 1, it is thought that approximately 1 g of water/g of dry solute's hydration water causes refreezing during the thawing process, that is, the amount of water that causes refreezing is about the same as the weight of the solute. When the solute is 3% of the total water, the amount of hydration water to be refrozen is still 3% of the total water.
It is thought that the shock in that case can be prevented if at least 3% of the total water content of ice is sublimated, and the amount of mannitol used for freeze-drying is generally 1 to 10% of the total water content. %, it is sufficient to sublimate a minimum amount of 1% water at the beginning of the process.

本発明によつて、何ら材質、肉厚、形状等の点
で特殊な容器を使う必要がなく、マンニトールが
高濃度に存在するものであつても、ビーカー等の
衝撃に弱い容器を用いることができるので、凍結
乾燥物の調製が極めて簡便になつた。
According to the present invention, there is no need to use a special container in terms of material, wall thickness, shape, etc., and even if mannitol is present in a high concentration, a container that is weak against impact such as a beaker can be used. As a result, the preparation of freeze-dried products has become extremely simple.

実施例 2 マンニトール100mg、シイタケ子実体より分離
された制癌性多糖レンチナン5mg、および「デキ
ストラン40」10mgを水2mlに溶解した水溶液を10
mlバイアルびんに入れ、実施例1に従つて凍結乾
燥を行つた。乾燥工程においてはまず−35℃〜25
℃において全水分の約10%の水分を気化せしめ
た。その後、自然昇温して乾燥した。ビーカーに
は何らひびや割れは生じなかつた。
Example 2 An aqueous solution prepared by dissolving 100 mg of mannitol, 5 mg of the anticancer polysaccharide lentinan isolated from the fruiting bodies of shiitake mushrooms, and 10 mg of "Dextran 40" in 2 ml of water was
ml vial and freeze-dried according to Example 1. In the drying process, first -35℃~25℃
Approximately 10% of the total water was vaporized at ℃. After that, it was naturally heated and dried. There were no cracks or cracks in the beaker.

このようにして製造された凍結乾燥品125mgを
水5mlに加え、バイアルびん中で4回かるく振つ
たら、均一水溶液が得られた。これに対し、従来
法(凍結工程における品温の冷却速度:0.5度/
分)により凍結乾燥した製品は、色の反射による
ものか着色し、外観が悪く、同様に125mgを水5
mlに加え、バイアルびん中で4回振つても均一水
溶液は得られず、7回振つたところで均一水溶液
が得られた。
125 mg of the lyophilized product thus produced was added to 5 ml of water and shaken 4 times in a vial to obtain a homogeneous aqueous solution. In contrast, the conventional method (cooling rate of product temperature in freezing process: 0.5 degrees/
The product freeze-dried (125 mg) with 5 minutes of water was colored, probably due to color reflection, and had a poor appearance.
ml and was shaken four times in a vial, no homogeneous aqueous solution was obtained, but a homogeneous aqueous solution was obtained after shaking seven times.

【図面の簡単な説明】[Brief explanation of drawings]

図1および図2は、実施例1で求めた凍結−解
凍曲線である。実線:凍結曲線、破線:解凍曲
線。
1 and 2 are freeze-thaw curves obtained in Example 1. Solid line: freezing curve, dashed line: thawing curve.

Claims (1)

【特許請求の範囲】 1 マンニトール含有水性溶液の凍結乾燥方法に
おいて、凍結工程における品温の冷却速度が少な
くとも1度/分であることを特徴とする凍結乾燥
方法。 2 マンニトール含有水性溶液におけるマンニト
ール濃度が全水分に対し1〜10%である特許請求
の範囲第1項記載の方法。 3 品温の冷却速度が2〜4度/分である特許請
求の範囲第1項記載の方法。
[Scope of Claims] 1. A freeze-drying method for an aqueous solution containing mannitol, characterized in that the cooling rate of the product temperature in the freezing step is at least 1 degree/minute. 2. The method according to claim 1, wherein the mannitol concentration in the mannitol-containing aqueous solution is 1 to 10% based on the total water content. 3. The method according to claim 1, wherein the cooling rate of the product temperature is 2 to 4 degrees/minute.
JP1257981A 1981-01-30 1981-01-30 Freeze-drying method Granted JPS57128643A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP1257981A JPS57128643A (en) 1981-01-30 1981-01-30 Freeze-drying method

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP1257981A JPS57128643A (en) 1981-01-30 1981-01-30 Freeze-drying method

Publications (2)

Publication Number Publication Date
JPS57128643A JPS57128643A (en) 1982-08-10
JPH0255410B2 true JPH0255410B2 (en) 1990-11-27

Family

ID=11809261

Family Applications (1)

Application Number Title Priority Date Filing Date
JP1257981A Granted JPS57128643A (en) 1981-01-30 1981-01-30 Freeze-drying method

Country Status (1)

Country Link
JP (1) JPS57128643A (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104387232A (en) * 2014-11-11 2015-03-04 常州大学 Method for extracting mannose from sea vegetable

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5612580A (en) * 1979-07-13 1981-02-06 Rhythm Watch Co Ltd Alarm setting device for clock

Also Published As

Publication number Publication date
JPS57128643A (en) 1982-08-10

Similar Documents

Publication Publication Date Title
US6684524B1 (en) Lyopohilization method
EP3136030B1 (en) Lyophilization method
EP1982133B1 (en) Method of inducing nucleation of a material
EP0394050B1 (en) A method of preparing a freeze-dried formulation containing a drug
CN101379356B (en) Method of inducing nucleation of a material
Maulny et al. Physical properties of co‐crystalline sugar and honey
IE42955B1 (en) Method of preparing stable sterile crystalline cephalosporins for parenteral administration
JPH0255410B2 (en)
JP7792906B2 (en) Freeze-dried preparation containing cephalosporins having a catechol group and method for producing the same
US4002748A (en) Method of preparing sterile essentially amorphous cefazolin for reconstitution for parenteral administration
JPS5874103A (en) Rack for refrigerating dryer
US7323572B2 (en) Process for controlling the hydrate mix of a compound
JP2988631B2 (en) Lyophilized preparation of fosfomycin sodium and method for producing the same
CN102166198A (en) Stable naloxone hydrochloride freeze-dry preparation and preparation method thereof
US3734902A (en) Highly soluble glucoside compositions and method of preparing same
JPS6019759B2 (en) For parenteral administration 11115152139199 2-3-13 Kyobashi, Chuo-ku, Tokyo
EP1534721B1 (en) Process for controlling the hydrate mix of the disodium salt of fosfluconazole
JPH0466202B2 (en)
HK40087588A (en) Lyophilized formulation containing cephalosporin having catechol group, and method for producing same
FI68055B (en) FOERFARANDE FOER FRAMSTAELLNING AV ETT SNABBLOESLIGT PULVER AVRISTALLINT CEFALOTINNATRIUM
WO2013006224A1 (en) Methods for freezing and thawing proteins
Kaiser Sugar and Its Role in Freeze-Drying Processes− Investigated by Means of DSC
CZ279454B6 (en) Process for preparing dry injections of cis-diaminedichloroplatinum complex
IE83615B1 (en) A method of preparing a freeze-dried formulation containing a drug
HK1010685B (en) A method of preparing a freeze-dried formulation containing a drug